Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis C

  Free Subscription


Articles published in Transplantation

Retrieve available abstracts of 56 articles:
HTML format



Single Articles


    May 2021
  1. MUTHUKUMAR T, Akat KM, Yang H, Schwartz JE, et al
    Serum MicroRNA Transcriptomics and Acute Rejection or Recurrent Hepatitis C Virus in Human Liver Allograft Recipients: A Pilot Study.
    Transplantation. 2021 May 11. pii: 00007890-900000000-95253.
    PubMed     Abstract available


    February 2021
  2. CALABRESE DR
    Ribavirin to the Rescue: Natural Killer Cell Function After Hepatitis C Virus Treatment in Liver Transplant Recipients.
    Transplantation. 2021 Feb 12. pii: 00007890-900000000-95359.
    PubMed    


  3. YOELI D, Choudhury RA, Moore HB, Sauaia A, et al
    Are Hepatitis C Positive Female Liver Transplant Recipients Still at Increased Risk for Graft Failure? Re-Examining the Disparity in the Modern Era of Direct Acting Antiviral Agents.
    Transplantation. 2021 Feb 11. pii: 00007890-900000000-95364.
    PubMed     Abstract available


  4. HUCKABY LV, Seese LM, Handzel R, Wang Y, et al
    Center-level Utilization of Hepatitis C Virus Positive Donors for Orthotopic Heart Transplantation.
    Transplantation. 2021 Feb 8. doi: 10.1097/TP.0000000000003674.
    PubMed     Abstract available


    January 2021
  5. FUJISAKI T, Mikami T, Kuno T, Moss N, et al
    Effect of Hepatitis C Virus Infection on Heart Transplants in the Current Era.
    Transplantation. 2021 Jan 25. pii: 00007890-900000000-95404.
    PubMed     Abstract available


    October 2020
  6. NGUYEN T, Sise ME, Delgado C, Williams W, et al
    Race, Education, and Gender Disparities in Transplantation of Kidneys from Hepatitis C Viremic Donors.
    Transplantation. 2020 Oct 29. doi: 10.1097/TP.0000000000003511.
    PubMed     Abstract available


    June 2020
  7. COTTER TG, Aronsohn A, Reddy KG, Charlton M, et al
    Liver Transplantation of HCV-Viremic Donors into HCV-Negative Recipients in the USA: Increasing Frequency with Profound Geographic Variation.
    Transplantation. 2020 Jun 29. doi: 10.1097/TP.0000000000003382.
    PubMed     Abstract available


  8. BAE S, Durand CM, Garonzik-Wang JM, Chow EKH, et al
    Antithymocyte Globulin Versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients With Hepatitis C Virus.
    Transplantation. 2020;104:1294-1303.
    PubMed     Abstract available


    March 2020
  9. HENSON JB, Wilder JM, Kappus MR, Barbas AS, et al
    Transplant Outcomes in Older Patients with Nonalcoholic Steatohepatitis Compared to Alcohol-Related Liver Disease and Hepatitis C.
    Transplantation. 2020 Mar 6. doi: 10.1097/TP.0000000000003219.
    PubMed     Abstract available


    January 2020
  10. GORGEN A, Galvin Z, Huang AC, Vinaixa C, et al
    The Impact of Direct Acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients with Hepatocellular Carcinoma Listed for Liver Transplantation.: An International Multicenter Study.
    Transplantation. 2020 Jan 16. doi: 10.1097/TP.0000000000003115.
    PubMed     Abstract available


    November 2019
  11. KAHN J, Terrault NA
    Intentional Transmission of Hepatitis C With Organ Transplantation: With Opportunity Comes Responsibility.
    Transplantation. 2019;103:2215-2216.
    PubMed    


    October 2019
  12. BURTON JR JR, Terrault NA, Goldberg DS, Bloom RD, et al
    Liver and Kidney Recipient Selection of HCV-Viremic Donors - Meeting Consensus Report from the 2019 Controversies in Transplantation.
    Transplantation. 2019 Oct 18. doi: 10.1097/TP.0000000000003014.
    PubMed     Abstract available


    September 2019
  13. BAE S, Durand CM, Garonzik-Wang JM, Chow EKH, et al
    Anti-Thymocyte Globulin versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients with Hepatitis C Virus.
    Transplantation. 2019 Sep 13. doi: 10.1097/TP.0000000000002959.
    PubMed     Abstract available


  14. CANNON RM, Locke JE, Orandi BJ, Anderson DJ, et al
    Impact of donor hepatitis C virus on kidney transplant outcomes for hepatitis C positive recipients in the direct acting antiviral era: time to revise the kidney donor risk index?
    Transplantation. 2019 Sep 9. doi: 10.1097/TP.0000000000002949.
    PubMed     Abstract available


  15. HUANG E
    Hepatitis C Infection in Kidney Donors: A Call to Re-examine its Relevance as a Predictor of Transplant Outcomes.
    Transplantation. 2019 Sep 3. doi: 10.1097/TP.0000000000002950.
    PubMed    


    August 2019
  16. WEEKS SR, Luo X, Haugen CE, Ottmann SE, et al
    Delayed graft function in simultaneous liver kidney transplantation.
    Transplantation. 2019 Aug 8. doi: 10.1097/TP.0000000000002908.
    PubMed     Abstract available


    October 2018
  17. CHARLTON MR, Gane EJ, Shukla A, Dashtseren B, et al
    International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting - From Noncirrhotic to Decompensated Disease and Following Liver Transplantation.
    Transplantation. 2018 Oct 17. doi: 10.1097/TP.0000000000002453.
    PubMed     Abstract available



  18. Successful Treatment of Chronic Hepatitis C Virus Infection with Sofosbuvir and Ledipasvir in Renal Transplant Recipients: Erratum.
    Transplantation. 2018;102:e458.
    PubMed    


    September 2018
  19. CROOME KP, Mathur AK, Pungpapong S, Lee DD, et al
    Equivalent Outcomes with Retransplantation and Primary Liver Transplantation in the Direct Acting Antiviral Era.
    Transplantation. 2018 Sep 21. doi: 10.1097/TP.0000000000002460.
    PubMed     Abstract available


    July 2018
  20. SAGESHIMA J, Troppmann C, McVicar JP, Santhanakrishnan C, et al
    Impact of Willingness to Accept Hepatitis C Seropositive Kidneys Among Hepatitis C RNA-Positive Waitlisted Patients.
    Transplantation. 2018;102:1179-1187.
    PubMed     Abstract available


    June 2018
  21. BOWRING MG, Kucirka LM, Massie AB, Ishaque T, et al
    Changes in utilization and discard of HCV-antibody positive deceased-donor kidneys in the era of direct-acting antiviral therapy.
    Transplantation. 2018 Jun 13. doi: 10.1097/TP.0000000000002323.
    PubMed     Abstract available


    May 2018
  22. TUCCI A, Rizza S, Cocchis D, Martini S, et al
    Early and late hepatitis B reactivation following IFN- or DAA-based therapy of recurrent hepatitis C in anti-HBc-positive liver transplant recipients.
    Transplantation. 2018 May 2. doi: 10.1097/TP.0000000000002241.
    PubMed    


    February 2018
  23. DI MAIRA T, Torregrosa A, Navarro V, Sanchez D, et al
    Liver Volume as a Predictor of Functional Improvement Post-DAA Treatment.
    Transplantation. 2018;102:e74-e81.
    PubMed     Abstract available


    January 2018
  24. MCCAULEY M, Mussell A, Goldberg D, Sawinski D, et al
    Race, Risk, and Willingness of End-stage Renal Disease Patients Without Hepatitis C (HCV) to Accept an HCV-infected Kidney Transplant.
    Transplantation. 2018 Jan 18. doi: 10.1097/TP.0000000000002099.
    PubMed     Abstract available


    November 2017
  25. TROTTER PB, Summers DM, Ushiro-Lumb I, Robb M, et al
    Use of organs from hepatitis C virus positive donors for uninfected recipients: a potential cost-effective approach to save lives?
    Transplantation. 2017 Nov 22. doi: 10.1097/TP.0000000000002033.
    PubMed     Abstract available


  26. AGARWAL N, Davis RJ, Gracey DM, Wong G, et al
    Detection of Hepatitis C antibodies without viral transmission in Hepatitis C negative recipients receiving kidneys from Hepatitis C positive donors treated with Direct Acting Anti-Viral Therapy.
    Transplantation. 2017 Nov 22. doi: 10.1097/TP.0000000000002034.
    PubMed    


  27. HOLSCHER CM, Durand CM, Desai NM
    Expanding the Use of Organs from Hepatitis C-Viremic Donors: The Evidence Continues to Build.
    Transplantation. 2017 Nov 22. doi: 10.1097/TP.0000000000002032.
    PubMed    


    October 2017
  28. HEO NY, Mannalithara A, Kim D, Udompap P, et al
    Long-term Patient and Graft Survival of Kidney Transplant Recipients with Hepatitis C Virus Infection in the United States.
    Transplantation. 2017 Oct 3. doi: 10.1097/TP.0000000000001953.
    PubMed     Abstract available


    August 2017
  29. ANTONINI TM, Coilly A, Rossignol E, Fougerou-Leurent C, et al
    Sofosbuvir-based Regimens in HIV/HCV Coinfected Patients after Liver Transplantation: Results from the ANRS CO23 CUPILT Study.
    Transplantation. 2017 Aug 24. doi: 10.1097/TP.0000000000001928.
    PubMed     Abstract available


  30. CHOLANKERIL G, Li AA, Yoo ER, Ahmed A, et al
    Direct-Acting Antiviral Therapy and Improvement in Graft Survival of Hepatitis C Liver Transplant Recipients.
    Transplantation. 2017 Aug 24. doi: 10.1097/TP.0000000000001926.
    PubMed    


  31. GARCIA CR, Acosta LF, Mei X, Berger J, et al
    Liver Transplantation for the Treatment of Complicated Iatrogenic Biliary Injuries: A National Review from the UNOS Dataset.
    Transplantation. 2017 Aug 22. doi: 10.1097/TP.0000000000001922.
    PubMed     Abstract available


  32. ABAALKHAIL F, Elsiesy H, Elbeshbeshy H, Shawkat M, et al
    Treatment of Patients With Hepatitis C Virus infection (Genotype 4) With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.
    Transplantation. 2017 Aug 9. doi: 10.1097/TP.0000000000001907.
    PubMed     Abstract available


    July 2017
  33. WALLER KMJ, Wyburn KR, Shackel NA, O'Leary MJ, et al
    Hepatitis transmission risk in kidney transplantation (the HINT study): a cross-sectional survey of transplant clinicians in Australian and New Zealand.
    Transplantation. 2017 Jul 21. doi: 10.1097/TP.0000000000001885.
    PubMed     Abstract available


  34. PRUETT TL, Clark MA, Taranto SE
    Deceased Organ Donors and PHS Risk Identification: Impact on Organ Usage and Outcomes.
    Transplantation. 2017;101:1670-1678.
    PubMed     Abstract available


  35. VOLK ML, Wilk AR, Wolfe C, Kaul DR, et al
    The "PHS Increased Risk" Label Is Associated With Nonutilization of Hundreds of Organs per Year.
    Transplantation. 2017;101:1666-1669.
    PubMed     Abstract available


    May 2017
  36. SINGH N, Dies D, Samant H
    Hepatitis C-Positive Kidney Transplant Recipients-When Is The Best Time to Treat With Direct-Acting Antiviral Agents?
    Transplantation. 2017;101:e192.
    PubMed    


  37. TERRAULT NA, Berenguer M, Strasser SI, Gadano A, et al
    International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients.
    Transplantation. 2017;101:956-967.
    PubMed    


  38. TERRAULT NA, McCaughan GW, Curry MP, Gane E, et al
    International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates.
    Transplantation. 2017;101:945-955.
    PubMed    


  39. TAPPER EB, Afdhal NH, Curry MP
    Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C.
    Transplantation. 2017;101:933-937.
    PubMed     Abstract available


    April 2017
  40. MARTIN MT, Koppe S
    Elbasvir/Grazoprevir Use in Postliver Transplantation Patients on Hemodialysis.
    Transplantation. 2017 Apr 3. doi: 10.1097/TP.0000000000001758.
    PubMed     Abstract available


    March 2017
  41. TERRAULT N, Berenguer M, Strasser S, Gadano A, et al
    International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT RECIPIENTS.
    Transplantation. 2017 Mar 1. doi: 10.1097/TP.0000000000001704.
    PubMed    


  42. TERRAULT NA, McCaughan GW, Curry MP, Gane E, et al
    International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES.
    Transplantation. 2017 Mar 1. doi: 10.1097/TP.0000000000001708.
    PubMed    


  43. ARONSOHN A
    Timing is Everything: Managing Hepatitis C in Liver Transplant Candidates.
    Transplantation. 2017 Mar 1. doi: 10.1097/TP.0000000000001703.
    PubMed    


    February 2017
  44. VERNA EC, Brown RS Jr
    HCV Antiviral Therapy In Liver Transplant Candidates and Recipients with Renal Insufficiency.
    Transplantation. 2017 Feb 16. doi: 10.1097/TP.0000000000001688.
    PubMed     Abstract available


  45. SANTOS AH JR, Casey MJ, Xuerong W, Womer KL, et al
    Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States.
    Transplantation. 2017;101:377-386.
    PubMed     Abstract available


    January 2017
  46. VINAIXA C, Strasser SI, Berenguer M
    DISEASE REVERSIBILITY IN PATIENTS WITH POSTHEPATITIS C CIRRHOSIS: IS THE POINT OF NO RETURN THE SAME BEFORE AND AFTER LIVER TRANSPLANTATION? A REVIEW.
    Transplantation. 2017 Jan 6. doi: 10.1097/TP.0000000000001633.
    PubMed     Abstract available



  47. Impact of Cytomegalovirus Infection on Severe Hepatitis C Recurrence in Patients Undergoing Liver Transplantation: Erratum.
    Transplantation. 2017;101:e40.
    PubMed    


    December 2016
  48. DEBES JD, de Knegt RJ, Boonstra A
    The path to cancer, and back: Immune modulation during hepatitis C virus infection, progression to fibrosis and cancer, and unexpected roles of new antivirals.
    Transplantation. 2016 Dec 30. doi: 10.1097/TP.0000000000001623.
    PubMed     Abstract available


  49. LUBETZKY M, Chun S, Joelson A, Coco M, et al
    Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients with Directly Acting Antiviral Agents.
    Transplantation. 2016 Dec 22. doi: 10.1097/TP.0000000000001618.
    PubMed     Abstract available


  50. WERNER JM, Adenugba A, Protzer U
    Immune reconstitution following HCV clearance with direct antiviral agents: potential consequences for patients with HCC?
    Transplantation. 2016.
    PubMed     Abstract available


  51. SALAZAR J, Saxena V, Kahn JG, Roberts JP, et al
    Cost-Effectiveness of Direct-Acting Anti-viral Treatment in Hepatitis C-infected Liver Transplant Candidates with Compensated Cirrhosis and Hepatocellular Carcinoma.
    Transplantation. 2016.
    PubMed     Abstract available


  52. CARRILLO CF, Crespo G, de la Revilla J, Castells L, et al
    Successful continuation of HCV treatment following liver transplantation.
    Transplantation. 2016.
    PubMed     Abstract available


  53. CROOME KP, Lee DD, Keaveny AP, Taner CB, et al
    Improving National Results in Liver Transplantation Using Grafts From Donation After Cardiac Death Donors.
    Transplantation. 2016;100:2640-2647.
    PubMed     Abstract available


    November 2016
  54. BARBIER L, Cesaretti M, Dondero F, Cauchy F, et al
    Liver Transplantation With Older Donors: A Comparison With Younger Donors in a Context of Organ Shortage.
    Transplantation. 2016;100:2410-2415.
    PubMed     Abstract available


    September 2016
  55. ELFEKI M, Abou Mrad R, Modaresi Esfeh J, Zein N, et al
    Sofosbuvir/Ledipasvir without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence after Liver Transplantation: Two-Center Experience.
    Transplantation. 2016.
    PubMed     Abstract available


    April 2016
  56. BRAUN HJ, Dodge JL, Roll GR, Freise CE, et al
    Impact of Graft Selection on Donor and Recipient Outcomes After Living Donor Liver Transplantation.
    Transplantation. 2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: